BioNTech (NASDAQ:BNTX) Upgraded at Evercore ISI

Evercore ISI upgraded shares of BioNTech (NASDAQ:BNTX) from an in-line rating to an outperform rating in a report published on Tuesday morning, Marketbeat.com reports. They currently have $125.00 price objective on the stock, up from their prior price objective of $110.00.

A number of other equities research analysts have also issued reports on BNTX. TD Cowen cut their price target on shares of BioNTech from $132.00 to $122.00 and set a “hold” rating on the stock in a report on Tuesday, November 5th. Morgan Stanley upgraded shares of BioNTech from an “equal weight” rating to an “overweight” rating and upped their price objective for the company from $93.00 to $145.00 in a research note on Tuesday, September 24th. Jefferies Financial Group raised shares of BioNTech from a “hold” rating to a “buy” rating and lifted their target price for the company from $96.00 to $150.00 in a research note on Tuesday, September 17th. JPMorgan Chase & Co. reduced their price objective on BioNTech from $125.00 to $124.00 and set a “neutral” rating for the company in a research report on Monday, November 4th. Finally, HSBC raised their price objective on shares of BioNTech from $97.00 to $136.00 and gave the company a “buy” rating in a research report on Monday, October 7th. Four research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $138.79.

BioNTech Trading Up 4.4 %

BioNTech stock opened at $106.40 on Tuesday. The company has a quick ratio of 7.21, a current ratio of 7.33 and a debt-to-equity ratio of 0.01. The firm has a 50-day moving average price of $113.68 and a two-hundred day moving average price of $97.45. The firm has a market capitalization of $25.51 billion, a price-to-earnings ratio of -50.67 and a beta of 0.26. BioNTech has a 52-week low of $76.53 and a 52-week high of $131.49.

BioNTech (NASDAQ:BNTX) last released its quarterly earnings results on Monday, November 4th. The company reported $0.81 EPS for the quarter, topping analysts’ consensus estimates of ($1.26) by $2.07. BioNTech had a negative net margin of 15.16% and a negative return on equity of 2.35%. The company had revenue of $1.24 billion for the quarter, compared to the consensus estimate of $514.08 million. During the same period in the previous year, the firm earned $0.73 EPS. BioNTech’s revenue was up 38.9% on a year-over-year basis. Sell-side analysts expect that BioNTech will post -3.68 earnings per share for the current year.

Hedge Funds Weigh In On BioNTech

A number of institutional investors have recently bought and sold shares of the business. Covestor Ltd grew its position in shares of BioNTech by 47.2% in the first quarter. Covestor Ltd now owns 415 shares of the company’s stock valued at $38,000 after purchasing an additional 133 shares during the last quarter. Planning Capital Management Corp boosted its stake in shares of BioNTech by 45,000.0% in the third quarter. Planning Capital Management Corp now owns 451 shares of the company’s stock valued at $54,000 after buying an additional 450 shares during the period. Blue Trust Inc. boosted its stake in shares of BioNTech by 491.1% in the third quarter. Blue Trust Inc. now owns 467 shares of the company’s stock valued at $55,000 after buying an additional 388 shares during the period. EverSource Wealth Advisors LLC boosted its stake in shares of BioNTech by 106.3% in the first quarter. EverSource Wealth Advisors LLC now owns 489 shares of the company’s stock valued at $43,000 after buying an additional 252 shares during the period. Finally, GAMMA Investing LLC boosted its stake in shares of BioNTech by 86.9% in the second quarter. GAMMA Investing LLC now owns 512 shares of the company’s stock valued at $41,000 after buying an additional 238 shares during the period. Institutional investors and hedge funds own 15.52% of the company’s stock.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.